Last reviewed 2026-05-20 · How we verify

Droprenylamine (DROPRENILAMINE)

Phase 2 active Small molecule ✓ Verified May 2026

Droprenylamine (generic name: DROPRENILAMINE) is a drug. It is currently in Phase 2 development.

Droprenylamine is a small molecule that works by binding to specific biological molecules to produce a therapeutic effect.

Droprenylamine is a small molecule with the synonyms DROPRENILAMINA, DROPRENILAMINE, and MG-8926.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	DROPRENILAMINE
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like a city with many different buildings. Droprenylamine is like a key that unlocks a specific building, allowing the city's processes to work more efficiently. This can help to treat various diseases, but the exact building it unlocks and how it helps is still unknown.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Droprenylamine CI brief — competitive landscape report
Droprenylamine updates RSS · CI watch RSS

Frequently asked questions about Droprenylamine

What is Droprenylamine?

Droprenylamine (DROPRENILAMINE) is a Small molecule drug.

How does Droprenylamine work?

Droprenylamine is a small molecule that works by binding to specific biological molecules to produce a therapeutic effect.

What is the generic name of Droprenylamine?

DROPRENILAMINE is the generic (nonproprietary) name of Droprenylamine.

What development phase is Droprenylamine in?

Droprenylamine is in Phase 2.

Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing